Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer

Abstract

Gemcitabine has been used as a key drug for the treatment of pancreatic ductal adenocarcinoma. Although surgery remains the mainstay for cure of this lethal disease, the effect is quite limited, even for resectable disease, if there is no collaboration with chemotherapy. In the cases with unresectable disease, conversion surgery after a favorable response to chemotherapy might show encouraging results. Potentiation of chemotherapeutic agent is urgently needed in almost all stages of pancreatic cancer. Further efforts must be paid on overcoming chemo-resistance by understanding tumor diversity and developing biomarkers that follow recent success of modified conventional agents by drug delivery technology.

Keywords

Gemcitabine / chemo-resistance / pancreatic cancer / multi-modal therapy / surgery

References

[1] Saiki Y,Horii A.Attempts to remodel the pathways of gemcitabine metabolism: recent approaches to overcoming tumours with acquired chemoresistance.Cancer Drug Resist2020;3:819-31

[2] Von Hoff DD,Arena FP.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med2013;369:1691-703 PMCID:PMC4631139

[3] Wang-gillam A,Bodoky G.Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.Lancet2016;387:545-57

[4] Jang JY,Han Y.Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study.J Hepatobiliary Pancreat Sci2017;24:426-33

[5] Matsumoto I,Shinzeki M.Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study.Pancreatology2015;15:674-80

[6] Motoi F,Katayose Y,Unno M.Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines.Ann Surg Oncol2011;18:371-9

[7] Motoi F,Okada KI.Multicenter Study Group of Pancreatobiliary Surgery (MSG-PBS)Sustained elevation of postoperative serum level of carbohydrate antigen 19-9 is high-risk stigmata for primary hepatic recurrence in patients with curatively resected pancreatic adenocarcinoma.World J Surg2019;43:634-41

[8] Parmar A,Saluja R.Adjuvant treatment for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.Crit Rev Oncol Hematol2020;145:102817

[9] Oettle H,Hochhaus A.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.JAMA2013;310:1473-81

[10] Neoptolemos JP,Ghaneh P.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.Lancet2017;389:1011-24

[11] Uesaka K,Fukutomi A.Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).Lancet2016;388:248-57

[12] Conroy T,Hebbar M.Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE GroupFOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.N Engl J Med2018;379:2395-406

[13] Motoi F,Ueno H.Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP)Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).Jpn J Clin Oncol2019;49:190-4

[14] Unno M,Matsuyama Y.Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).J Clin Oncol2019;37:189

[15] Birrer DL,Casadei R.Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. Pooled data from three randomized controlled trials.Ann Surg2021;

[16] Satoi S,Kato K.Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.J Hepatobiliary Pancreat Sci2013;20:590-600

[17] Murphy JE,Ryan DP.Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial.JAMA Oncol2019;5:1020-7 PMCID:PMC6547247

[18] Philip PA,Portales F.Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.Lancet Gastroenterol Hepatol2020;5:285-94

[19] Adam RS,Ten Hoorn S,Vermeulen L.The recurring features of molecular subtypes in distinct gastrointestinal malignancies-A systematic review.Crit Rev Oncol Hematol2021;164:103428

[20] Randazzo O,Mantini G."Open Sesame?": biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer.Cancers (Basel)2020;12:3206 PMCID:PMC7692081